Tianyan Hu, United States of America
Merck & Co., Kenilworth, NJ USA Center for Observational and Real-World EvidencePoster Author Of 3 e-Posters
HEALTH AND ECONOMIC BURDEN ASSOCIATED WITH 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (V114) SEROTYPES IN CANADIAN CHILDREN
A RETROSPECTIVE DATABASE ANALYSIS TO ESTIMATE THE BURDEN OF PNEUMONIA IN CHILDREN
A RETROSPECTIVE DATABASE ANALYSIS TO ESTIMATE THE BURDEN OF INVASIVE PNEUMOCOCCAL DISEASE AND UNSPECIFIED INVASIVE DISEASE IN CHILDREN
Presenter of 1 Presentation
HEALTH AND ECONOMIC BURDEN ASSOCIATED WITH 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (V114) SEROTYPES IN CANADIAN CHILDREN (ID 706)
Abstract
Background
A 15-valent pneumococcal conjugate vaccine (V114) containing PCV13 serotypes and 22F/33F is under development. This study quantifies the health and economic burden of V114-type pneumococcal disease in Canadian children.
Methods
V114-type invasive pneumococcal disease (IPD) and acute otitis media (AOM) cases were simulated in a single, unvaccinated cohort from birth to 20 years with a Markov model. In the pre-PCV scenario, pre-PCV7 epidemiological inputs were used. In the post-PCV scenario, pre-PCV7, pre-PCV13 and current-day inputs were used to estimate PCV7, PCV13 not PCV7 (PCV13-PCV7), and 22F/33F disease, respectively. Costs were estimated from a societal perspective and discounted at 1.5%.
Results
In the pre-PCV scenario, 600 V114-type IPD cases were attributable to PCV7 serotypes (n=535, 89%), PCV13-PCV7 serotypes (n=56, 9%), and 22F/33F (n=9, 2%); 715,642 V114-type AOM outpatient visits were attributable to PCV7 serotypes (n=519,286, 73%), PCV13-PCV7 serotypes (n=189,864, 27%), and 22F/33F (n=6,491, 1%). Total costs for V114-type IPD and AOM were CA$274 million. In the post-PCV scenario, PCV13-PCV7 serotypes increased, specifically serotypes 3, 19A and 7F for IPD, and 19A for AOM.
Conclusions
PCV7 serotypes cause most pneumococcal morbidity and are important to retain in PCVs. Select PCV13-PCV7 serotypes also contribute to the disease burden. Including non-vaccine serotypes can prevent additional disease burden.
Author Of 3 Presentations
HEALTH AND ECONOMIC BURDEN ASSOCIATED WITH 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (V114) SEROTYPES IN CANADIAN CHILDREN (ID 706)
Abstract
Background
A 15-valent pneumococcal conjugate vaccine (V114) containing PCV13 serotypes and 22F/33F is under development. This study quantifies the health and economic burden of V114-type pneumococcal disease in Canadian children.
Methods
V114-type invasive pneumococcal disease (IPD) and acute otitis media (AOM) cases were simulated in a single, unvaccinated cohort from birth to 20 years with a Markov model. In the pre-PCV scenario, pre-PCV7 epidemiological inputs were used. In the post-PCV scenario, pre-PCV7, pre-PCV13 and current-day inputs were used to estimate PCV7, PCV13 not PCV7 (PCV13-PCV7), and 22F/33F disease, respectively. Costs were estimated from a societal perspective and discounted at 1.5%.
Results
In the pre-PCV scenario, 600 V114-type IPD cases were attributable to PCV7 serotypes (n=535, 89%), PCV13-PCV7 serotypes (n=56, 9%), and 22F/33F (n=9, 2%); 715,642 V114-type AOM outpatient visits were attributable to PCV7 serotypes (n=519,286, 73%), PCV13-PCV7 serotypes (n=189,864, 27%), and 22F/33F (n=6,491, 1%). Total costs for V114-type IPD and AOM were CA$274 million. In the post-PCV scenario, PCV13-PCV7 serotypes increased, specifically serotypes 3, 19A and 7F for IPD, and 19A for AOM.
Conclusions
PCV7 serotypes cause most pneumococcal morbidity and are important to retain in PCVs. Select PCV13-PCV7 serotypes also contribute to the disease burden. Including non-vaccine serotypes can prevent additional disease burden.
A RETROSPECTIVE DATABASE ANALYSIS TO ESTIMATE THE BURDEN OF PNEUMONIA IN CHILDREN (ID 782)
Abstract
Background
Streptococcus pneumoniae is a leading cause of bacterial pneumonia in children. This analysis assessed pneumonia incidence rates (IRs) and expenditures following PCV13 introduction in 2010 in Veneto.
Methods
Outpatient pneumococcal and unspecified pneumonia episodes in children <15 years in the Veneto Region were identified in the Pedianet database from 2010-2017. IRs were numbers of episodes/1,000 person-years. Interrupted time series (ITS) analysis were conducted to assess trends in annual IRs in the early and late PCV13 (2010-2013, 2014-2017) periods.
Results
Incidence was higher in children 2-4 years, compared to children <2 and 5-14 years. IRs declined from 14/1,000 person-years in 2010 to 5/1,000 person-years in 2017 in the total cohort.
In ITS analysis, a significant downward trend was detected in the late PCV13 period (p =0.0027) with rates declining by 2.8% annually in children under 15 years. Mann-Kendall test showed a significant negative correlation over the analysis period (coef=-0.64, p=0.026). Similar results were found for children 2-4 and 5-14 years but not in children < 2 years.
Total regional expenditures declined from €472,573 in 2010 to €157,865 in 2017.
Conclusions
Results demonstrate a decrease in outpatient pneumonia incidence and regional expenditures in children <15 years after PCV13 introduction with greater benefits in older children.
A RETROSPECTIVE DATABASE ANALYSIS TO ESTIMATE THE BURDEN OF INVASIVE PNEUMOCOCCAL DISEASE AND UNSPECIFIED INVASIVE DISEASE IN CHILDREN (ID 788)
Abstract
Background
Invasive pneumococcal disease (IPD) is associated with high mortality and healthcare utilization. This analysis assessed IPD and unspecified invasive disease incidence rates (IRs) following PCV13 introduction in 2010 in Veneto.
Methods
IPD and unspecified invasive disease episodes in children <15 years in the Veneto region were identified in the Pedianet database from 2010-2017. IPD and unspecified invasive disease included pneumococcal and unspecified bacteremia, meningitis and septicemia. IRs were numbers of episodes/100,000 person-years. Interrupted time series (ITS) analyses assessed trends in annual IRs in the early and late PCV13 (2010-2013, 2014-2017) periods.
Results
We identified 81 episodes of IPD and unspecified invasive disease over the analysis period of which 94% were associated with non-specific codes.
IPD and unspecified invasive disease incidence decreased from 40/100,000 person-years (95% CI: 17-63/100,000 person-years) in 2010 to 31/100,000 person-years (95% CI: 6-56/100,000 person-years) in 2017 in children <15 years. While incidence was numerically lower in 2017 than in 2010, ITS analysis did not detect a significant trend in the early (coef=1.97; p=0.63) or late PCV13 (coef=0.50; p=0.90) periods.
Conclusions
Results did not show a significant decrease in IPD and unspecified invasive disease incidence in children <15 years after PCV13 introduction in Veneto.